Neuropathy and chronic pain · cardiovascular risk screening

Neuropathy and Chronic Pain as Cardiovascular Risk Markers: The Screening Signal in Plain Sight

Peripheral neuropathy and chronic pain are cardiovascular risk markers. In NHANES, neuropathy found on monofilament testing was tied to higher cardiovascular mortality in adults with diabetes (HR 1.66), and in the UK Biobank chronic widespread pain carried a 48% higher adjusted risk of cardiovascular disease. A patient who presents with burning feet or daily pain warrants a cardiometabolic and autonomic workup.

The patient with burning feet gets a gabapentinoid. The patient with diffuse pain gets a referral to rheumatology. Neither usually gets a cardiovascular risk assessment beyond the lipid panel already on file. The cohort data say both should.

How strongly does peripheral neuropathy predict death?

Hicks and colleagues followed 7,116 NHANES participants aged 40 and older who had standardized monofilament testing between 1999 and 2004. Neuropathy prevalence was 13.5% overall: 27.0% with diabetes and 11.6% without. Over a median 13 years, 2,128 died, 488 from cardiovascular causes.

All-cause mortality per 1,000 person-years ran 13.0 with neither diabetes nor neuropathy, 27.1 with diabetes alone, 34.3 with neuropathy alone and 57.6 with both. After adjustment, neuropathy was associated with all-cause mortality (HR 1.49) and cardiovascular mortality (HR 1.66) in participants with diabetes. Without diabetes, the all-cause association held (HR 1.31); the cardiovascular association (HR 1.27, 95% CI 0.98 to 1.66) did not reach significance.

Two things follow. Neuropathy without diabetes carried a higher crude death rate than diabetes without neuropathy. And the case definition was a monofilament, which detects large-fiber loss; small-fiber disease, which the monofilament misses, was not counted. The true burden is likely underestimated.

What does cardiovascular autonomic neuropathy add?

Autonomic involvement is the part of neuropathy that reaches the heart directly. Maser’s meta-analysis of 15 studies in diabetes found a pooled relative risk of mortality of 3.45 (95% CI 2.66 to 4.47) when cardiovascular autonomic neuropathy was defined by two or more abnormal tests, against 1.20 when a single measure was used. In ACCORD, among 8,135 participants with type 2 diabetes at high cardiovascular risk, baseline autonomic dysfunction defined by heart rate variability and QT index carried 1.55 to 2.14 times the mortality risk, depending on the definition, over a mean 3.5 years.

The practical lesson is in Maser’s split. A single abnormal heart rate variability value is a weak signal; a battery that confirms dysfunction on two or more tests is a strong one. That argues for cardiac autonomic reflex tests alongside heart rate variability, not either alone.

Is chronic pain itself a cardiovascular risk factor?

In the UK Biobank, Rönnegård and colleagues classified 475,171 participants by pain duration and distribution and followed them for a median of seven years. After adjusting for age, sex, established cardiovascular risk factors, physical activity, anxiety, depression, cancer, chronic inflammatory disease, pain and anti-inflammatory medication and socioeconomic status, chronic localized pain carried an HR of 1.14 and chronic widespread pain an HR of 1.48 for composite cardiovascular disease. The population attributable risk for chronic pain was 8.6%, against 7.3% for diabetes.

A 2026 meta-analysis of 18 studies on chronic widespread pain narrows the claim honestly. The risk of atherosclerotic disease was elevated in minimally adjusted models (RR 1.94) and remained elevated in maximally adjusted models (RR 1.53, 95% CI 1.27 to 1.86). For cardiovascular mortality the minimally adjusted RR was 1.61 but fell to 1.12 (95% CI 0.93 to 1.34) with full adjustment, heterogeneity was high, and publication bias was suspected in the mortality analysis. The atherosclerosis signal is consistent; the mortality signal is not settled. The authors’ conclusion is the screening argument: people with widespread pain may be an under-recognized high-risk group that would benefit from proactive cardiovascular assessment.

What biology links nerves, pain and arteries?

Shared terrain rather than a single pathway. Adiposity predicts neuropathy independent of glycemia. In KORA F4/FF4, 513 adults aged 62 to 81 followed for 6.5 years, obesity carried an OR of 3.47 for incident distal sensorimotor polyneuropathy and each 5 cm of waist an OR of 1.22, with no difference by diabetes status. The chemokines CCL7 and CXCL10 each mediated up to 11% of the effect. Callaghan found polyneuropathy in 3.8% of lean controls and 11.1% of normoglycemic participants with obesity, rising to 29% with prediabetes and 34.6% with diabetes; waist circumference was independently associated.

At the nerve, cytokines, chemokines and lipid mediators from inflamed tissue sensitize nociceptors and promote the maladaptive plasticity that sustains neuropathic pain. The same metabolic inflammation drives insulin resistance and atherosclerosis. Then behavior closes the loop: pain reduces activity, fragments sleep and isolates people, and each of those worsens insulin resistance. NSAID exposure adds its own cardiovascular load; see NSAID cardiovascular risk in chronic pain.

What does the workup look like?

  • Small fibers: sudomotor testing, read against the device’s reference bands. Burning feet with a normal monofilament exam often point here; see fibromyalgia and small fiber neuropathy.
  • Autonomic: heart rate variability plus cardiac autonomic reflex tests, defining dysfunction on two or more abnormalities.
  • Vascular: ankle-brachial index and arterial stiffness, because neuropathic feet mask claudication.
  • Adiposity: waist and body composition.
  • Laboratory: LP-IR, fasting insulin and HOMA-IR (fasting insulin above 10 µIU/mL is treated as high risk at the Padda Institute), GGT (cutoff above 20 U/L), oxidized LDL with the omega-3 index and omega-6 to omega-3 ratio, hs-CRP, 25-OH vitamin D, homocysteine, and B12 with MMA or holotranscobalamin. The last three matter twice in this population because they are also neuropathy causes. See hyperinsulinemia screening in neuropathic pain.

Build it into intake for pain and neuropathy referrals through standing orders, and use specialty applications for the pain-practice version of the workflow.

Dr. Padda has worn an EKG through his own heat-exposure experiments and watched his rhythm change in real time. The autonomic nervous system is not an abstraction on a report; it is the wiring between how a person lives and how their heart behaves, and in a pain patient it is usually already frayed.

Frequently asked questions

Does treating neuropathy or pain lower cardiovascular risk?

That has not been shown in a trial. Maser’s meta-analysis closed by calling for studies of whether early identification of autonomic neuropathy reduces mortality. The value of screening now is finding the shared drivers, adiposity, insulin resistance and inflammation, that are treatable and that the pain presentation would otherwise hide.

Is a normal monofilament exam enough to rule out neuropathy-related risk?

No. The monofilament detects large-fiber loss. Small-fiber and autonomic involvement can be present with a normal monofilament, which is why sudomotor and autonomic testing belong in the screen.

Add the cardiovascular screen to your nerve and pain patients

Sudomotor, autonomic, vascular and body composition testing in one visit, with a report written for the referring physician.

4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

References

  • Hicks, C. W., Wang, D., Matsushita, K., Windham, B. G., & Selvin, E. (2021). Peripheral Neuropathy and All-Cause and Cardiovascular Mortality in U.S. Adults : A Prospective Cohort Study. Annals of Internal Medicine, 174(2), 167-174. https://doi.org/10.7326/M20-1340 (PMID 33284680)
  • Maser, R. E., Mitchell, B. D., Vinik, A. I., & Freeman, R. (2003). The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care, 26(6), 1895-1901. https://doi.org/10.2337/diacare.26.6.1895 (PMID 12766130)
  • Pop-Busui, R., Evans, G. W., Gerstein, H. C., Fonseca, V., Fleg, J. L., Hoogwerf, B. J., et al. (2010). Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care, 33(7), 1578-1584. https://doi.org/10.2337/dc10-0125 (PMID 20215456)
  • Rönnegård, A.-S., Nowak, C., Äng, B., & Ärnlöv, J. (2022). The association between short-term, chronic localized and chronic widespread pain and risk for cardiovascular disease in the UK Biobank. European Journal of Preventive Cardiology, 29(15), 1994-2002. https://doi.org/10.1093/eurjpc/zwac127 (PMID 35727954)
  • Rönnegård, A.-S., Schillemans, T., Äng, B., Boersma, K., Ärnlöv, J., & Tseli, E. (2026). Chronic widespread pain and the risk of cardiovascular disease-a systematic review and meta-analysis. Pain, 167(6), 1295-1307. https://doi.org/10.1097/j.pain.0000000000003965 (PMID 41972388)
  • Schlesinger, S., Herder, C., Kannenberg, J. M., Huth, C., Carstensen-Kirberg, M., Rathmann, W., et al. (2019). General and Abdominal Obesity and Incident Distal Sensorimotor Polyneuropathy: Insights Into Inflammatory Biomarkers as Potential Mediators in the KORA F4/FF4 Cohort. Diabetes Care, 42(2), 240-247. https://doi.org/10.2337/dc18-1842 (PMID 30523031)
  • Callaghan, B. C., Xia, R., Reynolds, E., Banerjee, M., Rothberg, A. E., Burant, C. F., et al. (2016). Association Between Metabolic Syndrome Components and Polyneuropathy in an Obese Population. JAMA Neurology, 73(12), 1468-1476. https://doi.org/10.1001/jamaneurol.2016.3745 (PMID 27802497)
  • Ellis, A., & Bennett, D. L. H. (2013). Neuroinflammation and the generation of neuropathic pain. British Journal of Anaesthesia, 111(1), 26-37. https://doi.org/10.1093/bja/aet128 (PMID 23794642)
  • Hotamisligil, G. S. (2017). Inflammation, metaflammation and immunometabolic disorders. Nature, 542(7640), 177-185. https://doi.org/10.1038/nature21363 (PMID 28179656)

Related reading

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed .

Filed under: